Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis.

J Microbiol Immunol Infect · 2022 · PMC9359495 · PMID 35995666

Europe PMC DOI

hedged sentence

0.4800

closest p · 9.6× alpha

0.4800

boldest claim

The sentences

did not reach statistical significancep = 0.48not close (p > 0.1)

Overall, although the patients who received inhaled ciclesonide had higher rates of symptom resolution by day 7 and 14 than those in the control group, these differences did not reach statistical significance (day 7: RR, 1.08; 95% CI, 0.88–1.32; I 2 = 0, p = 0.48; day 14: RR, 1.09; 95% CI, 0.96–1.24; I 2 = 0, p = 0.18) ( Supplemental figure 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.